Features August 2010 Issue

Prostate Cancer Drugs Could Pose Risk to Heart Health

FDA reviewing safety of anti-hormone treatments due to links with heart disease and diabetes.

The Food and Drug Administration (FDA) has announced that it is investigating the safety of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs used to treat prostate cancer, after evidence linking them with a rise in the risk of heart disease and diabetes. Itís not the first time concerns have been raised about the use of hormone therapy to treat prostate canceróa 2009 study suggested it raises the risk of heart disease by as much as 25 percent

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.